IL6 and systemic sclerosis: To date, only two small molecule drugs, Nintedanib and Pirfenidone, have been approved for IPF, while Tocilizumab, an anti-IL-6 biologic, is approved for systemic sclerosis-associated interstitial lung disease (SSc-ILD) [1, 2], a related pathology.